Correlation between SATB1 and Bcl-2 expression in human glioblastoma multiforme
- Authors:
- Published online on: October 16, 2012 https://doi.org/10.3892/mmr.2012.1131
- Pages: 139-143
Abstract
Introduction
Glioblastoma multiforme (GBM) is the most common and lethal glial tumor of the adult brain, accounting for approximately 50% of all gliomas. GBM is characterized by an aggressive growth pattern, a marked degree of invasiveness and extremely poor prognosis. Even after multimodal treatment approaches, the median survival of patients with GBM following the primary diagnosis remains poor. An improved understanding of the genetic background and molecular pathogenic processes involved in the tumorigenesis of GBM is therefore critical for the development of rational, targeted therapies (1–5).
Special AT-rich sequence-binding protein 1 (SATB1) is a cell type-specific nuclear matrix attachment region-binding protein that links specific DNA elements to its cage-like network (6) and is predominantly expressed in thymocytes (7). SATB1 facilitates the formation of an open chromatin structure and is involved in the regulation of hundreds of genes. SATB1 has recently received considerable attention from the cancer research field due to high expression in various malignant tumor tissues (8–10), indicative of a tumor growth promoter. To explore the roles of SATB1 in the clinical progression of GBM, the present study examined the correlation between expression of SATB1 and Bcl-2 in GBM and tumor apoptosis, in order to shed new light on GBM therapy.
Materials and methods
Patients and tissue samples
Seventy cases of surgically resected GBMs were collected from the 2007–2010 pathology files of the Third People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and Zhongnan Hospital of Wuhan University. Approval was obtained from the Ethics committee of the Third People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and Zhongnan Hospital of Wuhan University. Specimens were handled and made anonymous according to ethical and legal standards. Written informed consent was obtained from all patients. There were 40 males and 30 females with a mean age of 46 years (range, 29–68). None of the patients had received chemical therapy or radiotherapy prior to surgery. Control brain tissues were obtained from 10 individuals, who had died in traffic accidents exhibiting no prior pathologically detectable condition. Based on the results of hematoxylin-eosin staining, histopathological diagnosis was performed by various neuropathologists.
In situ hybridization
Frozen sections were immersed in a solution of 30% hydrogen dioxide and methanol for 30 min following brief warming at room temperature, then incubated at 37°C with pepsin diluted by 3% citric acid. Sections were postfixed for 10 min in 1% paraformaldehyde and were incubated at 38–42°C with DIG-labeled antisense cRNA probes overnight in a humidified chamber. Following multiple washes in 4× SSC at room temperature, the slides were incubated at 37°C in a blocking reagent for 30 min, a biotinylated anti-digoxin antibody for 60 min, SABC for 20 min and the biotinylated peroxydase for 20 min, at 37°C, followed by staining with DAB (Sigma, St. Louis, MO, USA). Sections were then covered with glycerol-gelatin and coverslips for microscopic examination (11,12). The SATB1 probe (sequence: 5′-TCTTTAATTTCTAATATATTTAGAA-3′) was synthesized and labeled with biotin at the 5′ end by Sangon Bioengineering Technology and Services Co., Ltd. (Shanghai, China). The probe was replaced with the dilution solution in control samples.
Immunohistochemical analysis
Antigen retrieval was performed in boiling citrate buffer for 15 min. Peroxide blocking was performed with 0.3% peroxide in absolute methanol. The slides were then incubated with anti-Bcl-2 polyclonal antibody (diluted 1:300; Sigma) or mouse anti-PCNA monoclonal antibody (diluted 1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at 4°C overnight and washed twice with phosphate-buffered saline prior to incubation with a secondary antibody (Santa Cruz Biotechnology, Inc.) at room temperature for 30 min. After washing, the sections were incubated with immunoglobulins conjugated with horseradish peroxidase. The reaction was then developed with 3,3′-diaminobenzidine substrate (2,13). Tissue sections were counterstained with hematoxylin or methyl green.
Quantification of SATB1 mRNA, Bcl-2 and PCNA protein
The nucleoli of SATB1-positive cells, cytoplasm of Bcl-2-positive cells (14) and nuclei of PCNA-positive cells were stained brown-yellow. Images of the sections were obtained (magnification, ×100) using the HPIAS-1000 High Resolution Color Pathological Image Analysis System (Tongji Medical College Qianping Imaging Engineering Co., Ltd., Shanghai, China) (15). Specimens with a positive cell ratio <30% were defined as negative.
Measurement of apoptosis by flow cytometry
Tissues collected in RPMI-1640 medium supplemented with 10% fetal bovine serum were processed routinely to generate single-cell suspensions (16,17). Suspensions were then fixed in 70% cold ethanol, treated with 10 g/l RNase and suspended and stained with 10 g/l propidium iodine (PI). After washing with PBS, the cells were stained directly with PI at a final concentration of 10 μg/ml and 2% Annexin-V Flous (Roche, Basel, Swizerland) in incubation buffer for 10 min. The cells were collected by FACSCalibur (BD Pharmingen, San Diego, CA, USA) following instrument set-up with controls (non-treated, stained cells) and two washes in PBS. In this experiment, cells with early apoptotic signals (stained with Annexin V) and cells with late death signals (stained with PI) were quantified and apoptotic cells were analyzed using the CellQuest software (18,19). Each assay was performed in triplicate.
Statistical analysis
Quantitative values were expressed as the mean ± SD. Statistical analysis was performed using the Pearson method and a Student's or Chi-squared test using SPSS 12.0 (for Windows; SPSS, Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
SATB1 expression by in situ hybridization
The majority of brown-positive staining for in situ hybridization of SATB1 mRNA was homogeneously distributed within the nucleolus (Fig. 1A). SATB1 mRNA expression levels were found to be significantly higher in GBM than in the normal brain tissues (Fig. 1B; P<0.01).
Immunohistochemical analysis of Bcl-2 and PCNA protein expression
Immunohistochemical staining revealed Bcl-2 protein expression in both the cytoplasm and cell membrane (Fig. 1A). PCNA protein expression was primarily detected in the nucleolus (Fig. 1A). Expression of Bcl-2 and PCNA protein was noted at significantly higher levels in GBM tissues than in normal brain tissues (Fig. 1B, P<0.01).
Measurement of apoptosis by flow cytometry
To quantify apoptotic cell death in tissues, ~1×106 cells were double stained with Annexin V-FITC and PI at various times post-transfection. Apoptotic cell death was detected in GBM and normal brain tissues (Fig. 2A). FACS analysis identified a significantly higher number of apoptotic cells in GBM tissues than normal brain tissues (Fig. 2B; P<0.01).
Correlation between SATB1 and Bcl-2 expression and clinical characteristics of GBM
SATB1 mRNA and Bcl-2 protein expression levels were associated with the survival rate of patients (P<0.01), but were not associated with patient gender, age and tumor size and site (Table I).
Correlation between SATB1 and Bcl-2 expression, PCNA and apoptosis
Statistical analysis revealed a positive correlation between SATB1 mRNA and Bcl-2 protein levels (P<0.05) and between SATB1 mRNA and PCNA protein levels (P<0.01). A negative correlation was identified between SATB1 and apoptosis (P<0.01) and between Bcl-2 and apoptosis (P<0.01). However, a positive correlation was observed between Bcl-2 and PCNA (P<0.01), whereas a negative correlation was found between PCNA and apoptosis (P<0.01; Table II).
Co-expression of SATB1 and Bcl-2
SATB1-positive cases (+) were divided into two groups consisting of a survival rate <1 and ≥1 year. Differences between the groups were evaluated according to the Bcl-2 protein expression and identified as χ2=20.95 (P<0.001; Table III).
Discussion
SATB1 is a tissue-specific nuclear matrix-attachment DNA-binding protein, which is located on chromosome 3p23. SATB1 has previously attracted considerable attention in the cancer research field due to its high expression in tumor tissues of a variety of malignancies (8–10), indicative of a crucial role in the promotion of tumor growth and prediction of tumor prognosis. It was previously demonstrated that overexpression of SATB1 correlates with the metastatic potential of human gastric cancer and may be suitable for use as a novel independent prognostic marker for the prediction of gastric cancer outcome (20). Bcl-2 is expressed in various tissues under normal conditions, with the physiological function of the modulation of apoptotis and cell number balance (21). Two important factors of cell number control are rate of apoptosis and proliferation (22,23). Overexpression of SATB1 and/or Bcl-2 disturbs this balance and contributes to the proliferation and anti-apoptotic functions of the abnormal cell.
Results of the present study have demonstrated that expression of SATB1 mRNA and Bcl-2 protein is significantly higher in GBM tissues than in the normal brain tissues. With regard to clinical features, expression of SATB1 and Bcl-2 was correlated with patient survival, but was not associated with patient gender, age and tumor size and site. Overexpression of SATB1 mRNA and Bcl-2 protein was higher in the survival <1 year group than the ≥1 year and a significant positive correlation between SATB1 and Bcl-2 was observed. We analyzed the correlation between SATB1, Bcl-2, PCNA and apoptosis. A positive correlation between SATB1 mRNA and PCNA was observed. A negative correlation between SATB1 mRNA and apoptosis and between Bcl-2 and apoptosis was observed and a positive correlation was found between Bcl-2 and PCNA. These data suggest that SATB1 functions in the promotion of cell proliferation and inhibition of apoptosis. Function of Bcl-2 is restricted to inhibiting apoptosis. Consistent with this hypothesis, cases positive for SATB1 and Bcl-2 were associated with poor prognosis, thus, assessment of SATB1 and Bcl-2 co-expression may provide useful information for the diagnosis, therapy and prognosis of GBM.
Acknowledgements
This study was supported by grants from the Innovation Program of Shanghai Municipal Education Commission (12YZ046) and the New One Hundred Person Project of Shanghai Jiao Tong University of School of Medicine (10XBR01).
References
Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI | |
Chu SH, Ma YB, Feng DF, Zhang H, Zhu ZA, Li ZQ and Jiang PC: Correlation of low SLC22A18 expression with poor prognosis in patients with glioma. J Clin Neurosci. 19:95–98. 2012. View Article : Google Scholar : PubMed/NCBI | |
Chu SH, Feng DF, Ma YB, Zhang H, Zhu ZA, Li ZQ and Jiang PC: Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma. J Transl Med. 9:1562011. View Article : Google Scholar : PubMed/NCBI | |
Chu SH, Ma YB, Feng DF, Zhang H, Qiu JH and Zhu ZA: Effect of 5-Aza-2′-deoxycytidine on SLC22A18 in glioma U251 cells. Mol Med Rep. 5:138–141. 2012. | |
Yang FY, Teng MC, Lu M, Liang HF, Lee YR, Yen CC, Liang ML and Wong TT: Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound. Int J Nanomedicine. 7:965–974. 2012. View Article : Google Scholar : PubMed/NCBI | |
Kouzarides T: Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev. 9:40–48. 1999. View Article : Google Scholar | |
Dickinson LA, Joh T, Kohwi Y and Kohwi-Shigematsu T: A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell. 70:631–645. 1992. View Article : Google Scholar : PubMed/NCBI | |
Han HJ, Russo J, Kohwi Y and Kohwi-Shigematsu T: SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 452:187–193. 2008. View Article : Google Scholar : PubMed/NCBI | |
Meng WJ, Yan H, Zhou B, Zhang W, Kong XH, Wang R, Zhan L, Li Y, Zhou ZG and Sun XF: Correlation of SATB1 overexpression with the progression of human rectal cancer. Int J Colorectal Dis. 27:143–150. 2012. View Article : Google Scholar : PubMed/NCBI | |
Chen H, Takahara M, Oba J, Xie L, Chiba T, Takeuchi S, Tu Y, Nakahara T, Uchi H, Moroi Y and Furue M: Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma. J Dermatol Sci. 64:39–44. 2011. View Article : Google Scholar : PubMed/NCBI | |
Liu M, Xiao GG, Rong P, Zhang Z, Dong J, Zhao H, Li H, Li Y, Pan J, Liu H, Wang W, Zha Q and Ju D: Therapeutic effects of Radix Dipsaci, Pyrola Herb and Cynomorium Songaricum on bone metabolism of ovariectomized rats. BMC Complement Altern Med. 12:672012. | |
Chu SH, Yuan XH, Jiang PC, Li ZQ, Zhang J, Wen ZH, Zhao SY, Chen XJ and Cao CJ: The expression of hepatocyte growth factor and its receptor in brain astrocytomas. Zhonghua Yi Xue Za Zhi. 85:835–838. 2005.(In Chinese). | |
Chu SH, Feng DF, Ma YB, Zhang H, Zhu ZA, Li ZQ and Zhang ZH: Expression of HGF and VEGF in the cerebral tissue of adult rats with chronic hydrocephalus after subarachnoid hemorrhage. Mol Med Rep. 4:785–791. 2011.PubMed/NCBI | |
Chu SH, Ma YB, Feng DF, Zhang H, Qiu JH and Zhu ZA: Elevated expression of solute carrier family 22 member 18 increases the sensitivity of U251 glioma cells to BCNU. Oncol Lett. 2:1139–1142. 2011.PubMed/NCBI | |
Zhang H, Liu L, Huang G, Zhou L, Wu W, Zhang T and Huang H: Protective effect of electroacupuncture at the Neiguan point in a rabbit model of myocardial ischemia-reperfusion injury. Can J Cardiol. 25:359–363. 2009. View Article : Google Scholar : PubMed/NCBI | |
Demurtas A, Aliberti S, Bonello L, Di Celle PF, Cavaliere C, Barreca A, Novero D and Stacchini A: Usefulness of multiparametric flow cytometry in detecting composite lymphoma: study of 17 cases in a 12-year period. Am J Clin Pathol. 135:541–555. 2011.PubMed/NCBI | |
Wang E, Hutchinson CB, Huang Q, Lu CM, Crow J, Wang FF, Sebastian S, Rehder C, Lagoo A, Horwitz M, Rizzieri D, Yu J, Goodman B, Datto M and Buckley P: Donor cell-derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: a clinicopathologic study of 10 cases and a comprehensive review of the literature. Am J Clin Pathol. 135:525–540. 2011. View Article : Google Scholar | |
Chu SH, Feng DF, Zhang H, Chen ET, Duan ZX, Li XY, Li J, Ma YB, Zhu ZA and Qiu JH: c-Met-targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro. J Neurooncol. 93:183–189. 2009. View Article : Google Scholar : PubMed/NCBI | |
Chu S, Yuan X, Li Z, Jiang P and Zhang J: C-Met antisense oligodeoxynucleotide inhibits growth of glioma cells. Surg Neurol. 65:533–538. 2006. View Article : Google Scholar : PubMed/NCBI | |
Lu X, Cheng C, Zhu S, Yang Y, Zheng L, Wang G, Shu X, Wu K, Liu K and Tong Q: SATB1 is an independent prognostic marker for gastric cancer in a Chinese population. Oncol Rep. 24:981–987. 2010.PubMed/NCBI | |
Wensveen FM, Alves NL, Derks IA, Reedquist KA and Eldering E: Apoptosis induced by overall metabolic stress converges on the Bcl-2 family proteins Noxa and Mcl-1. Apoptosis. 16:708–721. 2011. View Article : Google Scholar : PubMed/NCBI | |
Zhang MS, Hu AH, Qiu H, Xiong HH and Chen Y: The correlation between IGF-II and Bcl-2 expression in colorectal adenocarcinoma. Med Oncol. 29:928–932. 2012. View Article : Google Scholar : PubMed/NCBI | |
An YL, Nie F, Wang ZY and Zhang DS: Preparation and characterization of realgar nanoparticles and their inhibitory effect on rat glioma cells. Int J Nanomedicine. 6:3187–3194. 2011. View Article : Google Scholar : PubMed/NCBI |